Yasumasa Nishimura1, Keiichi Jingu2, Satoshi Itasaka3, Yoshiharu Negoro4, Yuji Murakami5, Katsuyuki Karasawa6, Gen Kawaguchi7, Fumiaki Isohashi8, Masao Kobayashi9, Yoshiyuki Itoh10, Takuro Ariga11. 1. Department of Radiation Oncology, Kinki University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. ynishi@med.kindai.ac.jp. 2. Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan. 3. Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan. 4. Department of Radiology, Tenri Hospital, Tenri, Nara, 632-8552, Japan. 5. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, 734-8551, Japan. 6. Division of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, 113-8677, Japan. 7. Department of Radiation Oncology, Niigata University Medical and Dental Hospital, Niigata, 951-8510, Japan. 8. Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. 9. Department of Radiology, Jikei University School of Medicine, Tokyo, 105-8471, Japan. 10. Department of Radiology, Nagoya University, Nagoya, Aichi, 466-8550, Japan. 11. Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa, 903-0215, Japan.
Abstract
BACKGROUND: This second questionnaire-based survey was performed to determine the clinical results of definitive esophageal cancer treatment with radiotherapy (RT) or chemoradiotherapy (CRT) between 2004 and 2008. MATERIALS/ METHODS: Clinical results of definitive RT for patients were collected from major Japanese institutions. Patients were classified into three groups: (A) stage I, (B) resectable stages II-III, (C) unresectable stages III-IVA. For group A, all patients treated with RT alone or CRT were included. For groups B and C, only those treated with CRT were included. RESULTS: In total, 990 patients (group A 259, group B 333, group C 398 patients) were included from 11 institutions. In group A, 199 patients (78 %) were treated with CRT, and 60 patients (23 %) received RT alone. In groups B and C, 420 patients (57 %) were treated with full-dose cisplatin/5-FU, and 181 patients (25 %) with low-dose protracted-infusion cisplatin/5-FU. The median and range of the 5-year overall survival rate were 73 % (40-94 %) for group A, 40 % (0-57 %) for group B, and 18 % (6-26 %) for group C, respectively. The 5-year overall survival rates were consistently good for five high-volume centers where more than 20 patients/year with esophageal cancer were treated definitively as compared with the remaining six medium-volume centers (5-15 patients/year). The median and range of the incidence of grade ≥3 late toxicities were 10 % and 6-22 %, respectively. CONCLUSIONS: A wide disparity in 5-year overall survival rates among the institutions was still apparent in the second survey for groups A and B.
BACKGROUND: This second questionnaire-based survey was performed to determine the clinical results of definitive esophageal cancer treatment with radiotherapy (RT) or chemoradiotherapy (CRT) between 2004 and 2008. MATERIALS/ METHODS: Clinical results of definitive RT for patients were collected from major Japanese institutions. Patients were classified into three groups: (A) stage I, (B) resectable stages II-III, (C) unresectable stages III-IVA. For group A, all patients treated with RT alone or CRT were included. For groups B and C, only those treated with CRT were included. RESULTS: In total, 990 patients (group A 259, group B 333, group C 398 patients) were included from 11 institutions. In group A, 199 patients (78 %) were treated with CRT, and 60 patients (23 %) received RT alone. In groups B and C, 420 patients (57 %) were treated with full-dose cisplatin/5-FU, and 181 patients (25 %) with low-dose protracted-infusion cisplatin/5-FU. The median and range of the 5-year overall survival rate were 73 % (40-94 %) for group A, 40 % (0-57 %) for group B, and 18 % (6-26 %) for group C, respectively. The 5-year overall survival rates were consistently good for five high-volume centers where more than 20 patients/year with esophageal cancer were treated definitively as compared with the remaining six medium-volume centers (5-15 patients/year). The median and range of the incidence of grade ≥3 late toxicities were 10 % and 6-22 %, respectively. CONCLUSIONS: A wide disparity in 5-year overall survival rates among the institutions was still apparent in the second survey for groups A and B.
Entities:
Keywords:
Chemoradiation therapy; Clinical outcome; Esophageal cancer; National survey
Authors: M Murakami; Y Kuroda; T Nakajima; Y Okamoto; T Mizowaki; F Kusumi; K Hajiro; S Nishimura; S Matsusue; H Takeda Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman Journal: JAMA Date: 1999-05-05 Impact factor: 56.272
Authors: A Ohtsu; N Boku; K Muro; K Chin; M Muto; S Yoshida; M Satake; S Ishikura; T Ogino; Y Miyata; S Seki; K Kaneko; A Nakamura Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: M al-Sarraf; K Martz; A Herskovic; L Leichman; J S Brindle; V K Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: K Sakai; H Inakoshi; H Sueyama; J Oda; T Ito; E Tsuchida; T Sugita; Y Matsumoto; M Saito; A Saito Journal: Int J Radiat Oncol Biol Phys Date: 1995-02-15 Impact factor: 7.038